LTP
LTR PHARMA FPO [LTP]
Healthcare · ASX Small Cap
$0.4500 +0.0%
Updated 2026-03-02 · Scores refresh every scan
Appeared in 2 consecutive scans→ Score +0First seen: 2026-02-25
Score Breakdown
Technical48
Catalyst50
Sentiment50
Fundamental70
Momentum67
Risk Gate43
Active Signals
Bullish Signals
- RSI approaching oversold
- Stochastic oversold
- Strong cash runway (29 quarters)
- 4C filed 2026-01-27
- Very high P/S ratio (54.2x)
- Strong revenue growth (+2058%)
- Small-cap ($20-100M)
- Positive 12-1 momentum (+41%)
- Strong revenue momentum (+2058%)
- Altman Z-Score in grey zone (2.11)
- ASX200 bullish (+1.5% 5d)
- RBA cutting (+2pts)
Risk Signals
- Price below MAs (downtrend)
- Below 200-day MA (long-term downtrend)
- Insufficient sentiment data (defaulting to neutral)
- Neutral/mixed sentiment
Recent Catalysts
NONE Appendix 4D and Half Yearly Report
NONE Application for quotation of securities - LTP
NONE SPONTAN Shows Positive Outcomes in Younger Men with ED
LOW Quarterly Activities/Appendix 4C Cash Flow Report
MEDIUM First Patients Dosed in SPONTAN Phase II Clinical Study
Recent ASX Announcements
| 2026-02-25 | Appendix 4D and Half Yearly Report PRICE SENSITIVE |
| 2026-02-10 | Application for quotation of securities - LTP |
| 2026-02-01 | SPONTAN Shows Positive Outcomes in Younger Men with ED PRICE SENSITIVE |
| 2026-01-27 | Quarterly Activities/Appendix 4C Cash Flow Report PRICE SENSITIVE |
| 2026-01-21 | First Patients Dosed in SPONTAN Phase II Clinical Study PRICE SENSITIVE |
Key Metrics
$81.8M
Market Cap
221K
Avg Volume
1.0x
Vol Ratio
$0.27 — $0.81
52-Week Range
N/A
Short Interest
20 qtrs
Cash Runway
-32.5%
ROE
N/A
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 58% |
| L | Leader vs Laggard | laggard | RS: -0 |
| I | Institutional Sponsorship | insufficient_data | Inst: 0% |
| M | Market Direction | pass | Bullish |
Sector: Healthcare
Ranked #23 of 119 · Sector avg: 51
View all Healthcare signals →